Efficacy of the additional effect of hyperbaric... (2020 study) Skip to main content
Retrospective Study American journal of otolaryngology 2020

Efficacy of the additional effect of hyperbaric oxygen therapy in combination of systemic steroid and prostaglandin E(1) for idiopathic sudden sensorineural hearing loss.

Hara S, Kusunoki T, Honma H, Kidokoro Y, Ikeda K, American journal of otolaryngology, 2020

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The researchers looked back at the records of 67 patients with sudden hearing loss of unknown cause to compare hearing improvement with and without hyperbaric oxygen added to medicines.

What They Found

In this retrospective study of 67 patients with idiopathic sudden sensorineural hearing loss, patients who received hyperbaric oxygen therapy together with a systemic steroid and prostaglandin E1 showed greater hearing improvement than patients treated without it (p less than 0.01). The two treatment groups differed in some ways. After adjusting for confounding factors, a statistical analysis found a link between pure tone audiometry improvement and hyperbaric oxygen therapy (odds ratio 7.42, 95 percent confidence interval 2.37 to 23.3, p equals 0.001). The abstract as provided does not report the pressure used or the number of sessions.

What This Means for Canadian Patients

For people with sudden hearing loss of unknown cause, this study found that those who also had hyperbaric oxygen therapy alongside a steroid and prostaglandin E1 had greater hearing improvement than those who did not. Because this was a look back at past records and the groups were not the same, it shows an association and does not prove that the oxygen therapy caused the improvement. Anyone considering treatment should talk with their own physician.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The study was retrospective, and the abstract notes some differences between the two treatment groups, so the results may reflect those differences and not the treatment alone.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Retrospective Study
Category Sudden Hearing Loss
Source Pubmed
PubMed ID 31818456
Year Published 2020
Journal American journal of otolaryngology
MeSH Terms Aged; Alprostadil; Audiometry, Pure-Tone; Combined Modality Therapy; Drug Therapy, Combination; Female; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Humans; Hyperbaric Oxygenation; Male; Middle Aged; Prednisolone; Retrospective Studies

Cite This Study

Share

This study relates to Sudden Sensorineural Hearing Loss. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Sudden Hearing Loss

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: June 8, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology